Adoptive transfer of receptor-engineered T cells has produced impressive results in treating
patients with B cell leukemias and lymphomas. This success has captured public …

Over the past decade, the increased adoption of electroporation-based technologies has led
to an expansion of clinical research initiatives. Electroporation has been utilized in …

Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to
express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials …

Regulatory T (Treg) cells ensure tolerance against self-antigens, limit excessive
inflammation, and support tissue repair processes. Therefore, Treg cells are currently …

While initial approaches to adoptive T cell therapy relied on the identification and expansion
of rare tumour-reactive T cells, genetic engineering has transformed cancer immunotherapy …

Adoptive T cell therapy (ACT) is a rapidly evolving therapeutic approach designed to
harness T cell specificity and function to fight diseases. Based on the evidence that T …

Glioblastoma (GBM) is an aggressive central nervous system cancer with a dismal
prognosis. The standard of care involves surgical resection followed by radiotherapy and …

Chimeric antigen receptor T‐cells (CAR T‐cells) represent a novel and promising approach
in cancer immunotherapy. According to the World Health Organization (WHO), the number of …

Adoptive transfer of T cells expressing a transgenic T cell receptor (TCR) has the potential to
revolutionize immunotherapy of infectious diseases and cancer. However, the generation of …

Background CD133 is considered a marker for cancer stem cells (CSCs) in several types of
tumours, including hepatocellular carcinoma (HCC). Chimeric antigen receptor-specific T …